A5069436439- Systemic Lupus Erythematosus Research
- Pregnancy and Medication Impact
- Monoclonal and Polyclonal Antibodies Research
- Reproductive System and Pregnancy
- Renal Diseases and Glomerulopathies
- T-cell and B-cell Immunology
- Blood disorders and treatments
- Liver Diseases and Immunity
- Platelet Disorders and Treatments
- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- Chronic Lymphocytic Leukemia Research
- Parvovirus B19 Infection Studies
- Pharmaceutical studies and practices
- Hemophilia Treatment and Research
- Pregnancy and preeclampsia studies
- Aortic Thrombus and Embolism
- Eosinophilic Esophagitis
- Lung Cancer Treatments and Mutations
- Lipoproteins and Cardiovascular Health
- Cancer Immunotherapy and Biomarkers
- Immunodeficiency and Autoimmune Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Systemic Sclerosis and Related Diseases
- Urticaria and Related Conditions
University of Brescia
2011-2021
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2010-2019
Brescia University
2017
Marche Polytechnic University
2017
Center for Rheumatology
2015
University of Pavia
2013
Objective To investigate effectiveness and safety of belimumab in patients with active systemic lupus erythematosus (SLE) a clinical practice setting. Methods Sixty‐seven SLE, mean ± SD age 39.3 10.2 years, from 2 Italian prospective cohorts were treated (10 mg/kg on day 0, 14, 28, then every 28 days) added to background therapy. The Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI‐2K), the International Collaborating Clinics/American College Rheumatology Damage Index, Score...
To analyze complement level variations in systemic lupus erythematosus (SLE) pregnancies, focusing on disease flares and obstetric complications.SLE pregnancies prospectively followed by multidisciplinary teams from 1987 to 2018 2 Italian rheumatology centers were retrospectively analyzed. As reference, pregnancy-modified ranges of normal levels C3 C4 derived 175 the general population (GOP), as previously described our group.Two hundred forty-six 172 patients with SLE Eighty-nine percent...
Objective. To assess the longterm frequency of thrombotic recurrences, obstetrical complications, organ damage, severe comorbidities, and evolution toward connective tissue disease (CTD) in primary antiphospholipid syndrome (PAPS). Methods. Medical records patients with PAPS followed 6 centers for ≥ 15 years were retrospectively reviewed. Results. One hundred fifteen studied: 88% women, between 1983 2014 a mean (± SD) age at diagnosis 33 10) years. During median followup 18 (range 15–30), 50...
Introduction: Belimumab is a monoclonal antibody against soluble BLyS used for treatment of refractory Systemic Lupus Erythematosus (SLE). Although B cells are the main target this therapy, BLyS-dependent T cell activation pathway has also been demonstrated. The aim study to analyze and phenotype modifications in cohort SLE patients treated with belimumab correlation serum levels. Materials Methods: Fourteen were enrolled study. Lymphocyte immunophenotyping by flow cytometry determination...
Objective. To evaluate the association between serum complement levels (C3 and C4) obstetric complications. Methods. Fifty-seven pregnancies in primary APS (PAPS) patients were compared with 49 UCTD SS. A group of 175 healthy pregnant women studied to calculate a normality range for C3 C4 during pregnancy. Such was applied define hypocomplementaemia PAPS UCTD/SS. Results. Both groups (PAPS UCTD/SS) showed significantly lower each trimester as women; conversely, no significant difference...
Problem Cyclosporin A ( CYS A) is an immunosuppressant agent administered in autoimmune diseases, and its use during pregnancy lactation a debated topic. Method of study The demographic characteristics, the activity underlying disease, onset fetal–maternal complications have been investigated 21 consecutive patients (2 RA , 14 SLE 2 PA 1 SjS, DM Churg–Strauss vasculitis), treated with throughout 29 gestations. subanalysis group was performed. Results We recorded live birth rate 86.2%. median...
The aim was to determine whether assisted reproductive technologies (ARTs) confer additional risk in rheumatic patients (in terms of disease flare and fetal–maternal complications) whether, if performed, their efficacy is affected by maternal disease. Sixty infertile women undergoing 111 ART cycles were included. Clinical pregnancy rate, live birth flares maternal–fetal complications recorded. One hundred eleven 60 analysed. We reported 46 pregnancies (41.4%), 3 (3.1%) cases ovarian...
Objective To assess the prevalence of disease- and therapy-related complications organ damage after a follow-up 15 years or more in patients with primary antiphospholipid syndrome (PAPS). Methods Medical records prospectively followed our centre for at least were retrospectively reviewed. Results Thirty-five Caucasian (33 female, two male) diagnosis PAPS from 1984 to 2013 mean age onset 32 (SD 8.17) median 20.5 (range 15–30) included. The occurrence systemic autoimmune disease was observed...
Subcutaneous (SC) abatacept (ABA) is comparable to intravenous (IV) formulation in terms of efficacy and safety profile. Our work analyzed the switch SC from IV administration patients with rheumatoid arthritis.Fifty-one treated ABA were included. Clinical data obtained clinical charts.Fourteen relapsed needed return administration. Neither laboratory features nor previous therapies identified as risk factors for inefficacy. Disease activity decreased after infusions.SC showed a relapse 27%...
Abstract Objective The aim of this article is to assess the predictive value second trimester mean uterine artery Doppler pulsatility index (mUtA PI) for pregnancy complications in women with systemic lupus erythematosus (SLE). Methods Cohort study consecutive pregnancies complicated SLE during a period 12 years used. diagnosis was made before pregnancy. mUtA PI measured between 23 + 0 and 26 6 weeks' gestation. Pregnancy neonatal outcomes were collected. Small gestational age (SGA) defined...
<h3>Background</h3> Anti-TNFalfa agents are used to control disease activity in patients with Chronic Arthritides (Rheumatoid Arthritis, Psoriatic Ankylosing Spondylitis), often during the wash-out period of teratogenic DMARDs and usually discontinued at positive pregnancy index. However, presence a moderate severe maternal or puerperium may require use drugs also 2nd-3rd trimester and/or postpartum period. Few data available literature regarding their only anecdotal lactation....
<h3>Background</h3> Anti-TNFalfa agents have been used to control disease activity of patients with Chronic Arthritides (Rheumatoid Arthritis, Psoriatic Ankylosis Spondilitis) during the wash-out period teratogenic drugs. Patients flares pregnancy may also receive anti-TNFalfa 2nd-3rd trimester. <h3>Objectives</h3> To investigate health and developmental conditions children who were exposed <i>in utero</i> compare them non-exposed born women same disease. <h3>Methods</h3> An <i>ad-hoc</i>...
Abstract The concern about the offspring’s health is one of reasons for a reduced family size women with rheumatic diseases (RD). Increased risk autoimmune (AD) and neurodevelopmental disorders (ND) has been reported in children born to patients RD. Within nationwide survey reproductive issues RD, we aimed at exploring long-term outcome their children. By surveying 398 who received diagnosis RD during childbearing age (before 45), information offspring were obtained from 230 declared have...
Introduction: Antiphospholipid syndrome (APS) is a systemic autoimmune disease representing the most frequent cause of acquired hypercoagulability and recurrent miscarriages. The has been known for at least 30 years, but its treatment still strongly debated topic number reasons. First, it difficult, if not impossible, to identify univocal therapeutic regimen that will be effective every patient, given great clinical serological heterogeneity disease. Second, widely demonstrated positivity...
<h3>Background</h3> Data on the long-term outcome in primary antiphospholipid syndrome (PAPS) patients are still very limited. <h3>Objectives</h3> To assess frequency of recurrences, organ damage, severe comorbidities, mortality and evolution connective tissue disease (CTD) PAPS patients. <h3>Methods</h3> Medical records followed 6 centers for ≥15 years were retrospectively reviewed. Chi square categorical Student t test continuous variables used. P<0.05 was considered significant....